New insights on the possible role of mast cells in aspirin-induced asthma

Current Molecular Pharmacology

Volumn 2, Issue 2, 2009, Pages 182-189

  Mortaz, Esmaeil ^a,b,c   Engels, Ferdi ^a   Nijkamp, Frans P ^a   Redegeld, Frank A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c URMIA UNIVERSITY   (Iran)

Author keywords

Aspirin; Asthma; Leukotrienes; Mast cell; Nonsteroidal anti inflammatory drugs

Indexed keywords

8 ISOPROSTANE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; HEAT SHOCK PROTEIN; I KAPPA B; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOLEUKOTRIENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN SYNTHASE; PROTEIN TYROSINE PHOSPHATASE; TOLL LIKE RECEPTOR; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; HEAT SHOCK PROTEIN 70; LEUKOTRIENE; PHOSPHATASE; PROSTAGLANDIN F2 ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; CELL STIMULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRESS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; IMMUNOLOGY; METABOLISM; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; DINOPROST; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LEUKOTRIENES; MAST CELLS; PHOSPHORIC MONOESTER HYDROLASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TOLL-LIKE RECEPTORS;

EID: 77449107907     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467210902020182     Document Type: Article

References (85)

1. Hammad, H.; Lambrecht, B. N. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat. Rev. Immunol. 2008, 8, 193-204.
2. Jenneck, C.; Juergens, U.; Buecheler, M.; Novak, N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann. Allergy Asthma Immunol. 2007, 99, 13-21.
3. Pfaar, O.; Klimek, L. Eicosanoids, aspirin-intolerance and the upper airways--current standards and recent improvements of the desensitization therapy. J. Physiol. Pharmacol. 2006, 57(Suppl. 12), 5-13.
4. Szczeklik, A.; Stevenson D. D. Aspirin-induced asthma: advances in pathogenesis and management. J. Allergy Clin. Immunol. 1999, 104, 5-13.
5. Roumie, C. L.; Mitchel Jr., E. F.; Kaltenbach, L.; Arbogast, P. G.; Gideon, P.; Griffin, M. R. Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke. Stroke 2008, 39(7), 2037-2045.
6. Cai, Y.; Bjermer, L.; Halstensen, T. S. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am. J. Respir. Cell Mol. Biol. 2003, 29, 683-693.
7. Jawien, J.; Olszanecki, R.; Lorkowska, B.; Korbut, R. Effect of aspirin on cysteinyl leukotrienes production by eosinophils co- cultured with epithelial cells. J. Physiol. Pharmacol. 2004, 55, 765-772.
8. Jurivich, D. A.; Sistonen, L.; Kroes, R. A.; Morimoto, R. I. Effect of sodium salicylate on the human heat shock response. Science 1992, 255, 1243-1245.
9. Mortaz, E.; Redegeld, F. A.; Bloksma, N.; Dunsmore, K.; Denenberg, A.; Wong, H. R.; Nijkamp, F. P.; Engels, F. Induction of HSP70 is dispensable for anti-inflammatory action of heat shock or NSAIDs in mast cells. Exp. Hematol. 2006, 34, 414-423.
10. Voellmy, R.; Boellmann, F. Chaperone regulation of the heat shock protein response. Adv. Exp. Med. Biol. 2007, 594, 89-99.
11. Morimoto, R. I.; Kline, M. P.; Bimston, D. N.; Cotto, J. J. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem. 1997, 32, 17-29.
12. Berges-Gimeno, M. P.; Stevenson, D. D. Nonsteroidal anti- inflammatory drug-induced reactions and desensitization. J. Asthma 2004, 41, 375-384.
13. Castonguay, A.; Rioux, N.; Duperron, C.; Jalbert, G. Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp. Lung Res. 1998, 24, 605-615.
14. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 1998, 90, 1529-1536.
15. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 97-120.
16. Simon, L. S. Biologic effects of nonsteroidal anti-inflammatory drugs. Curr. Opin. Rheumatol. 1997, 9, 178-182.
17. Grosch, S.; Maier, T. J.; Schiffmann, S.; Geisslinger, G. Cyclooxy- genase-2 (COX-2)-independent anticarcinogenic effects of selec- tive COX-2 inhibitors. J. Natl. Cancer Inst. 2006, 98, 736-747.
18. Pillinger, M. H.; Capodici, C.; Rosenthal, P.; Kheterpal, N.; Hanft, S.; Philips, M. R.; Weissmann, G. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neu- trophil adhesion. Proc. Natl. Acad. Sci. USA 1998, 95, 14540-14545.
19. Casolaro, V.; Meliota, S.; Marino, O.; Patella, V.; de G. Guidi, P. A.; Marone, G. Nimesulide, a sulfonanilide nonsteroidal anti- inflammatory drug, inhibits mediator release from human basophils and mast cells. J. Pharmacol. Exp. Ther. 1993, 267, 1375-1385.
20. Tuynman, J. B.; Vermeulen, L.; Boon, E. M.; Kemper, K.; Zwinderman, A. H.; Peppelenbosch, M. P.; Richel, D. J. Cyclooxy- genase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68, 1213-1220.
21. Patrignani, P.; Capone, M. L.; Tacconelli, S. NSAIDs and cardio- vascular disease. Heart 2008, 94, 395-397.
22. Tegeder, I.; Adolph, J.; Schmidt, H.; Woolf, C. J.; Geisslinger, G.; Lotsch, J. Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur. J. Pain 2008, 12, 1069-1077.
23. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231, 232-235.
24. Mitchell, J. A.; Akarasereenont, P.; Thiemermann, C.; Flower, R. J.; Vane, J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 1993, 90, 11693-11697.
25. Weissmann, G. The actions of NSAIDs. Hosp. Pract. (Off Ed) 1991, 26, 60-8, 71-2, 75-6.
26. Weissmann, G. Aspirin. Sci. Am. 1991, 264, 84-90.
27. Brondello, J. M.; Pouyssegur, J.; McKenzie, F. R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999, 286, 2514-2517.
28. Brondello, J. M.; Brunet, A.; Pouyssegur, J.; McKenzie, F. R. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 1997, 272, 1368-1376.
29. Ono, M.; Okada, H.; Bolland, S.; Yanagi, S.; Kurosaki, T.; Ravetch, J. V. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 1997, 90, 293-301.
30. Lee, B. S.; Chen, J.; Angelidis, C.; Jurivich, D. A.; Morimoto, R. I. Pharmacological modulation of heat shock factor 1 by antiinflam- matory drugs results in protection against stress-induced cellular damage. Proc. Natl. Acad. Sci. USA 1995, 92, 7207-7211.
31. Earnest, D. L.; Hixson, L. J.; Alberts, D. S. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. Cell Biochem. 1992, 16I(Suppl.), 156-166.
32. Baoping, Y.; Guoyong, H.; Jieping, Y.; Zongxue, R.; Hesheng, L. Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase ac- tivity by blocking Akt/PKB activation in gastric cancer cell line. Dig. Dis. Sci. 2004, 49, 948-953.
33. Mortaz, E.; Redegeld, F. A.; Dunsmore, K.; Odoms, K.; Wong, H. R.; Nijkamp, F. P.; Engels, F. Stimulation of cysteinyl leukotriene production in mast cells by heat shock and acetylsalicylic acid. Eur. J. Pharmacol. 2007, 561, 214-219.
34. Reuter, S.; Taube, C. Mast cells and the development of allergic airway disease. J. Occup. Med. Toxicol. 2008, 3(Suppl. 1), S2.
35. Dubois, M. F.; Hovanessian, A. G.; Bensaude, O. Heat-shock- induced denaturation of proteins. Characterization of the insolubilization of the interferon-induced p68 kinase. J. Biol. Chem. 1991, 266, 9707-9711.
36. Snoeckx, L. H.; Cornelussen, R. N.; Van Nieuwenhoven, F. A.; Reneman, R. S.; D. Van, V. Heat shock proteins and cardiovascular pathophysiology. Physiol. Rev. 2001, 81, 1461-1497.
37. Szczeklik, A.; Sanak, M.; Nizankowska-Mogilnicka, E.; Kielbasa, B. Aspirin intolerance and the cyclooxygenase-leukotriene path- ways. Curr. Opin. Pulm. Med. 2004, 10, 51-56.
38. Soti, C.; Csermely, P. Pharmacological modulation of the heat shock response. Handb. Exp. Pharmacol. 2006, 417-436.
39. Chen, H.; Wu, Y.; Zhang, Y.; Jin, L.; Luo, L.; Xue, B.; Lu, C.; Zhang, X.; Yin, Z. Hsp70 inhibits lipopolysaccharide-induced NF- kappaB activation by interacting with TRAF6 and inhibiting its ubiquitination. FEBS Lett. 2006, 580, 3145-3152.
40. Kim, S. S.; Park, H. S.; Yoon, H. J.; Lee, Y. M.; Lee, S. K.; Nahm, D. H. Enhanced serum neutrophil chemotactic activity was noted in both early and late asthmatic responses during lysine-aspirin bron- choprovocation test in ASA-sensitive asthmatic patients. J. Korean Med. Sci. 2003, 18, 42-47.
41. Wang, R.; Kovalchin, J. T.; Muhlenkamp, P.; Chandawarkar, R. Y. Exogenous heat shock protein 70 binds macrophage lipid raft mi- crodomain and stimulates phagocytosis, processing, and MHC-II presentation of antigens. Blood 2006, 107, 1636-1642.
42. Gao, B.; Tsan, M. F. Induction of cytokines by heat shock proteins and endotoxin in murine macrophages. Biochem. Biophys. Res. Commun. 2004, 317, 1149-1154.
43. Giannessi, D.; Colotti, C.; Maltinti, M.; Del, R. S.; Prontera, C.; Turchi, S.; Labbate, A.; Neglia, D. Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricu- lar dysfunction: their relationships with myocardial and microvas- cular impairment. Cell Stress Chaperones 2007, 12, 265-274.
44. Rea, I. M.; McNerlan, S.; Pockley, A. G. Serum heat shock protein and anti-heat shock protein antibody levels in aging. Exp. Gerontol. 2001, 36, 341-352.
45. Martin-Ventura, J. L.; Leclercq, A.; Blanco-Colio, L. M.; Egido, J.; Rossignol, P.; Meilhac, O.; Michel, J. B. Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis 2007, 194, 334-341.
46. Dybdahl, B.; Wahba, A.; Lien, E.; Flo, T. H.; Waage, A.; Qureshi, N.; Sellevold, O. F.; Espevik, T.; Sundan, A. Inflammatory re- sponse after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002, 105, 685-690.
47. Mortaz, E.; Redegeld, F. A.; Nijkamp, F. P.; Wong, H. R.; Engels, F. Acetylsalicylic acid-induced release of HSP70 from mast cells results in cell activation through TLR pathway. Exp. Hematol. 2006, 34, 8-18.
48. Fuchs, B.; Braun, A. Modulation of asthma and allergy by address- ing toll-like receptor 2. J. Occup. Med. Toxicol. 2008, 3(Suppl 1), S5.
49. Tsujimoto, H.; Ono, S.; Efron, P. A.; Scumpia, P. O.; Moldawer, L. L.; Mochizuki, H. Role of Toll-like receptors in the development of sepsis. Shock 2008, 39, 315-321.
50. Gribar, S. C.; Anand, R. J.; Sodhi, C. P.; Hackam, D. J. The role of epithelial Toll-like receptor signaling in the pathogenesis of intesti- nal inflammation. J. Leukoc. Biol. 2008, 83, 493-498.
51. Salaun, B.; Romero, P.; Lebecque, S. Toll-like receptors' two- edged sword: when immunity meets apoptosis. Eur. J. Immunol. 2007, 37, 3311-3318.
52. Michel, O.; Duchateau, J.; Sergysels, R. Effect of inhaled endo- toxin on bronchial reactivity in asthmatic and normal subjects. J. Appl. Physiol. 1989, 66, 1059-1064.
53. Smith, T. F.; Aelvoet, M.; Morrison, D. C. The effect of bacterial lipopolysaccharide (LPS) on histamine release from human basophils. I. Enhancement of immunologic release by LPS. Clin. Immunol. Immunopathol. 1985, 34, 355-365.
54. Singh, I. S.; He, J. R.; Calderwood, S.; Hasday, J. D. A high affin- ity HSF-1 binding site in the 5'-untranslated region of the murine tumor necrosis factor-alpha gene is a transcriptional repressor. J. Biol. Chem. 2002, 277, 4981-4988.
55. Lee, K. H.; Lee, C. T.; Kim, Y. W.; Han, S. K.; Shim, Y. S.; Yoo, C. G. Preheating accelerates mitogen-activated protein (MAP) kinase inactivation post-heat shock via a heat shock protein 70- mediated increase in phosphorylated MAP kinase phosphatase-1. J. Biol. Chem. 2005, 280, 13179-13186.
56. Wong, H. R.; Dunsmore, K. E.; Page, K.; Shanley, T. P. Heat shock-mediated regulation of MKP-1. Am. J. Physiol. Cell Physiol. 2005, 289, C1152-C1158.
57. Sanlorenzo, L.; Zhao, B.; Spight, D.; Denenberg, A. G.; Page, K.; Wong, H. R.; Shanley, T. P. Heat shock inhibition of lipopolysac- charide-mediated tumor necrosis factor expression is associated with nuclear induction of MKP-1 and inhibition of mitogen- activated protein kinase activation. Crit. Care Med. 2004, 32, 2284-2292.
58. Antczak, A.; Montuschi, P.; Kharitonov, S.; Gorski, P.; Barnes, P. J. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in as- pirin-induced asthma. Am. J. Respir. Crit. Care Med. 2002, 166, 301-306.
59. Szczeklik, A.; Sladek, K.; Dworski, R.; Nizankowska, E.; Soja, J.; Sheller, J.; Oates, J. Bronchial aspirin challenge causes specific ei- cosanoid response in aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 1996, 154, 1608-1614.
60. Christie, P. E.; Tagari, P.; Ford-Hutchinson, A. W.; Black, C.; Markendorf, A.; Schmitz-Schumann, M.; Lee, T. H. Urinary leu- kotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am. Rev. Respir. Dis.1992, 146, 1531-1534.
61. Vassalle, C.; Botto, N.; Andreassi, M. G.; Berti, S.; Biagini, A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron. Artery Dis. 2003, 14, 213-218.
62. Lim, P. S.; Chang, Y. M.; Thien, L. M.; Wang, N. P.; Yang, C. C.; Chen, T. T.; Hsu, W. M. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Pu- rif. 2002, 20, 537-542.
63. Montuschi, P.; Collins, J. V.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S. A.; Barnes, P. J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 2000, 162, 1175-1177.
64. Mortaz, E.; Redegeld, F. A.; Nijkamp, F. P.; Engels, F. Aspirin induces the production of the inflammatory mediator 8-epi-PGF in mast cells. Eur. J. Pharmacol. 2006, 543, 190-193.
65. Janssen, L. J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 280, L1067-L1082.
66. Kim, S. H.; Hur, G. Y.; Choi, J. H.; Park, H. S. Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 2008, 9, 85-91.
67. Samter, M.; Beers Jr., R. F. Concerning the nature of intolerance to aspirin. J. Allergy 1967, 40, 281-293.
68. Sakakibara, H.; Yoneda, Y. [Aspirin-induced asthma (AIA)]. Nippon Rinsho 2005, 5(Suppl.), 114-119.
69. Chen, Y.; Ross, B. M.; Currie, R. W. Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta. Cell Stress Chaperones 2004, 9, 99-107.
70. Wang, X. S.; Wu, A. Y.; Leung, P. S.; Lau, H. Y. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease. Allergy 2007, 62, 620-627.
71. Szczeklik, A.; Musial, J.; Undas, A.; Sanak, M.; Nizankowski R. Aspirin resistance. Pharmacol. Rep. 2005, 57(Suppl.), 33-41.
72. Kim, S. H.; Yang, E. M.; Park, H. J.; Ye, Y. M.; Lee, H. Y.; Park, H. S. Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J. Clin. Immunol. 2007, 27, 613-619.
73. Kim, S. H.; Bae, J. S.; Holloway, J. W.; Lee, J. T.; Suh, C. H.; Nahm, D. H.; Park, H. S. A polymorphism of MS4A2 (- 109T > C) encoding the beta-chain of the high-affinity immunoglobulin E receptor (FcepsilonR1beta) is associated with a susceptibility to aspi- rin-intolerant asthma. Clin. Exp. Allergy 2006, 36, 877-883.
74. Mita, H.; Endoh, S.; Kudoh, M.; Kawagishi, Y.; Kobayashi, M.; Taniguchi, M.; Akiyama, K. Possible involvement of mast-cell ac- tivation in aspirin provocation of aspirin-induced asthma. Allergy 2001, 56, 1061-1067.
75. Gamboa, P.; Sanz, M. L.; Caballero, M. R.; Urrutia, I.; Antepara, I.; Esparza, R.; de Weck, A. L. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin. Exp. Allergy 2004, 34, 1448-1457.
76. Kowalski, M. L.; Grzegorczyk, J.; Wojciechowska, B.; Poniatowska, M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA- sensitive patients. Clin. Exp. Allergy 1996, 26, 807-814.
77. Szmidt, M.; Grzelewska-Rzymowska, I.; Rozniecki, J.; Kowalski, M. L.; Rychlicka, I. Histaminemia after aspirin challenge in aspi- rin-sensitive asthmatics. Agents Actions 1981, 11, 105-107.
78. Sladek, K.; Szczeklik, A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 1993, 6, 391-399.
79. Kumlin, M.; Dahlen, B.; Bjorck, T.; Zetterstrom, O.; Granstrom, E.; Dahlen, S. E. Urinary excretion of leukotriene E4 and 11- dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am. Rev. Respir. Dis. 1992, 146, 96-103.
80. Obase, Y.; Matsuse, H.; Shimoda, T.; Haahtela, T.; Kohno, S. Pathogenesis and management of aspirin-intolerant asthma. Treat. Respir. Med. 2005, 4, 325-336.
81. O'Sullivan, S.; Dahlen, B.; Dahlen, S. E.; Kumlin, M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 1996, 98, 421-432.
82. Galli, S. J.; Nakae, S.; Tsai, M. Mast cells in the development of adaptive immune responses. Nat. Immunol. 2005, 6, 135-142.
83. de Weck, A. L.; Gamboa, P. M.; Esparza, R.; Sanz, M. L. Hyper- sensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Curr. Pharm. Des. 2006, 12, 3347-3358.
84. Szczeklik, A.; Sanak, M. The broken balance in aspirin hypersensitivity. Eur. J. Pharmacol. 2006, 533, 145-155.
85. Mortaz, E.; Redegeld, F. A.; van der Heijden, M. W.; Wong, H. R.; Nijkamp, F. P.; Engels, F. Mast cell activation is differentially affected by heat shock. Exp. Hematol. 2005, 33, 944-952.